Key facts
- This page summarizes Jeff E. Knight's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 10 Apr 2026, 16:33.
Jeff E. Knight - 08 Apr 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)
- Reporting relationship
- Chief Dev. & Operating Officer
- Issuer ticker
- CRNX
- Reported as of
- 08 Apr 2026
- Net transaction value
- -$3,415,036
- SEC form
- 4
- Accepted by SEC
- 10 Apr 2026, 16:33:56 UTC
- Prior SEC filing
- 18 Mar 2026
- Next SEC filing
- 17 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tobin Schilke, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeff E. Knight filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 10 Apr 2026.
Change
- Previous filing in this sequence was filed on 18 Mar 2026.
- Current net transaction value: -$3,415,036.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001881007
Primary reporting owner
Knight Jeff E.
- Relationship
- Chief Dev. & Operating Officer
- Address
- C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO
- Signature
- /s/ Tobin Schilke, as attorney-in-fact
- Signature date
- 10 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRNX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +49,474
- Change %
- +44%
- Price
- $23.98*
- Shares after
- 161,492
- Date
- 08 Apr 2026
- Ownership
- Direct
CRNX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +9,624
- Change %
- +6%
- Price
- $20.02*
- Shares after
- 171,116
- Date
- 08 Apr 2026
- Ownership
- Direct
CRNX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +19,336
- Change %
- +11%
- Price
- $19.64*
- Shares after
- 190,452
- Date
- 08 Apr 2026
- Ownership
- Direct
CRNX
transaction
Common Stock
Sale
- Transaction value
- $3,415,036
- Shares
- -85,163
- Change %
- -45%
- Price
- $40.10
- Shares after
- 105,289
- Date
- 08 Apr 2026
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRNX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -49,474
- Change %
- -44%
- Price
- $0.000000*
- Shares after
- 63,027
- Date
- 08 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 49,474
- Exercise price
- $23.98
- Footnotes
- F3
CRNX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -9,624
- Change %
- -48%
- Price
- $0.000000*
- Shares after
- 10,589
- Date
- 08 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,624
- Exercise price
- $20.02
- Footnotes
- F4
CRNX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -19,336
- Change %
- -23%
- Price
- $0.000000*
- Shares after
- 65,977
- Date
- 08 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,336
- Exercise price
- $19.64
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
Footnote F2
The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sale price of $40.10 per share. The range of sale prices on the transaction date was $40.00 to $40.34. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
Footnote F3
25% of the shares subject to the option vested on August 30, 2022, and the remaining number of shares subject to the option vested monthly thereafter in thirty-six equal installments.
Footnote F4
1/48th of the shares subject to the option vested monthly measured from the vesting commencement date of February 28, 2022.
Footnote F5
The option is exercisable as follows: 1/48th of the shares subject to the option vest monthly measured from the vesting commencement date of March 1, 2023, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.